Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Aspirin has long been used for its analgesic, antipyretic, and antiplatelet properties. Interest in its role in oncology, particularly in CRC, has expanded over time. Its primary mechanism involves ...

Recent research from Massachusetts General Hospital and Harvard Medical School has uncovered aspirin‘s surprising protective effect against colorectal cancer, particularly among individuals with less ...

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be limited to individuals already at risk due to elevations in a particular ...

Researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer.

LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. Colorectal cancer (bowel cancer) is the third most common form of cancer worldwide, with around 1.9 ...